Stany Zjednoczone - angielski - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - von willebrand factor human (unii: ze22ne22f1) (von willebrand factor human - unii:ze22ne22f1) - von willebrand factor human 650 [iu] in 5 ml - vonvendi [von willebrand factor (recombinant)] is a recombinant von willebrand factor (rvwf) indicated for use in adults (age 18 and older) diagnosed with von willebrand disease (vwd) for: - on-demand treatment and control of bleeding episodes. - perioperative management of bleeding. - routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe type 3 vwd receiving on-demand therapy. vonvendi is contraindicated in patients who have had life-threatening hypersensitivity reactions to vonvendi or constituents of the product (tri-sodium citrate-dihydrate, glycine, mannitol, trehalose-dihydrate, polysorbate 80, and hamster or mouse proteins) [see description (11)] . risk summary adequate and well-controlled studies with vonvendi have not been conducted in pregnant women. animal developmental and reproductive toxicity studies have not been conducted with vonvendi. it is not known whether vonvendi can cause fetal harm when administered to a pregnant woman or whether it can affect reprodu

Malta - angielski - Medicines Authority

octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - human von, willebrand factor, human coagulation, factor viii - powder and solvent for solution for injection - human von willebrand factor 500 iu human coagulation factor viii 500 iu - antihemorrhagics

Malta - angielski - Medicines Authority

octapharma (ip) limited - human von willebrand factor; human coagulation factor viii - powder and solvent for solution for injection - human von willebrand factor 500 iu; human coagulation factor viii 500 iu - antihemorrhagics

Unia Europejska - angielski - EMA (European Medicines Agency)

csl behring gmbh - human coagulation factor viii, human von willebrand factor - hemophilia a; von willebrand diseases - blood coagulation factors, von willebrand factor and coagulation factor viii in combination, antihemorrhagics - von willebrand disease (vwd)prophylaxis and treatment of haemorrhage or surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated.haemophilia a (congenital factor-viii deficiency)prophylaxis and treatment of bleeding in patients with haemophilia a.

Malta - angielski - Medicines Authority

octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - human von, willebrand factor, human coagulation, factor xiii - powder and solvent for solution for injection - human von willebrand factor 1000 iu human coagulation factor viii 1000 iu - antihemorrhagics

Malta - angielski - Medicines Authority

octapharma (ip) limited - human von willebrand factor; human coagulation factor xiii - powder and solvent for solution for injection - human von willebrand factor 1000 iu; human coagulation factor xiii 1000 iu - antihemorrhagics

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

octapharma limited - factor viii (antihaemophilic factor), von willebrand factor human - pdr+solv for soln for inj - 1000/1000 international unit - blood coagulation factors

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

octapharma limited - factor viii (antihaemophilic factor), von willebrand factor human - pdr+solv for soln for inj - 500/500 international unit - blood coagulation factors

Australia - angielski - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 1000 iu; von willebrand factor, quantity: 2400 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 1200 iu; factor viii, quantity: 500 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.